Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Non-interventional, retrospective, single arm study of individuals who have initiated a DTG/3TC regimen. Medical chart will be reviewed by the investigators. Naive subjects will be identified by the clinic database as having initiated DTG/3TC.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DTG/3TC | Single arm cohort |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DTG + 3TC FDC | Drug | None(Non-interventional, retrospective chart review, single-arm study ) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients achieving viral suppression | Virological suppression is HIV RNA viral load < 50 copies/mL | At week 48 after DTG/3TC treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in CD4+cell counts | Change in CD4+ T-cell count from baseline | From baseline to week 48 |
| Persistence on DTG/3TC | The percentage of patients remaining on DTG/3TC over time after initiating DTG/3TC. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Estimated enrollment: 150-200 subjects.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yeon-sook kim | Chungnam National University Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chungnam National University Hospital, 282 Munwha-ro | Daejeon | 35015 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C562325 | dolutegravir |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At 48 weeks |
| Reasons for Discontinuation | Reason for discontinuation (HBV co-infection, Virological Failure, Blip, Simplification, Drug-drug Interactions, AE/SAE, Pregnancy, Cost, Patient Preference, Follow-up loss)) | Up to 48 weeks. |
| Changes in BMI | Changes from baseline BMI( kg/m^2) in treatment-Naive | From baseline to week 48 |
| Changes of lipid profile | Changes of lipid profile from basliene in treatment-Naive. These changes include increased levels of total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, triglycerides. | From baseline to week 48 |